Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives $82.33 Consensus Price Target from Brokerages
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock […]
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) has been assigned a consensus rating of “Buy” from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokers that have issued ratings on the stock […]
